In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS acquires diabetes player Amylin for $6.8bn

Executive Summary

After months of speculation that that it was up for sale and being pursued by multiple Big Pharma companies, publicly traded diabetes drug developer Amylin Pharmaceuticals Inc. announced it will be acquired by Bristol-Myers Squibb Co. for $6.8bn, consisting of $5.1bn in equity (based on 164mm outstanding Amylin shares) plus $1.7bn in combined Amylin net debt and a contractual payment that Amylin owes to Eli Lilly & Co. The $31-per-share cash price represents a 99% premium to the ten-day average leading up to late March 2012 reports that BMS had made a takeover bid.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies